RIGLHIGH SIGNALFINANCIAL10-K

RIGL experienced extraordinary financial performance with net income surging nearly 2000% to $367M and stockholders' equity jumping from $3.3M to $391.5M, while also divesting its GAVRETO asset based on language changes removing it from their commercial product portfolio.

This represents a transformational year for RIGL, with the massive increase in profitability and equity position suggesting either a major one-time gain (possibly from the GAVRETO divestiture) or exceptional operational performance from their remaining two commercial products. The removal of GAVRETO from their commercial product description indicates a strategic portfolio shift, likely generating significant cash proceeds that contributed to the dramatic financial improvement.

Comparing 2026-03-03 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

RIGL delivered exceptional financial results with revenue growing 64% to $294M, but the standout metrics were net income exploding nearly 2000% to $367M and stockholders' equity increasing over 11,000% to $391.5M, indicating either extraordinary operational performance or significant one-time gains. Operating cash flow more than doubled to $75.7M while the company expanded its balance sheet substantially with total assets growing 213% to $513.6M. The overall picture suggests a transformational year driven by strong commercial execution and likely strategic asset transactions that dramatically strengthened the company's financial position.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+11806.3%
$3.3M$391.5M

Equity base grew 11806.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
+1999.1%
$17.5M$367.0M

Net income grew 1999.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+418.6%
$24.2M$125.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Assets
Balance Sheet
+213.2%
$164.0M$513.6M

Asset base grew 213.2% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
+140.4%
$31.5M$75.7M

Operating cash flow surged 140.4% — exceptional cash generation, highest quality earnings signal.

Inventory
Balance Sheet
+91.7%
$6.0M$11.5M

Inventory surged 91.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+77.8%
$135.1M$240.2M

Current assets grew 77.8% — improving short-term liquidity or inventory/receivables build.

Revenue
P&L
+64.1%
$179.3M$294.3M

Strong top-line growth of 64.1% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+56.8%
$63.3M$99.2M

Current liabilities surged 56.8% — significant near-term obligations; verify ability to meet short-term debt.

R&D Expense
P&L
+42.4%
$23.4M$33.3M

R&D investment increased 42.4% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-04
ADDED
As of February 25, 2026, there were 18,473,130 shares of the registrant s common stock outstanding.
Our prospects are highly dependent on our existing commercial products.
TAVALISSE (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.
REZLIDHIA (olutasidenib) is our second FDA-approved product and indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
+7 more — sign up free →
REMOVED
As of February 25, 2025, there were 17,862,958 shares of the registrant s common stock outstanding.
Our prospects are highly dependent on our existing commercial products, TAVALISSE (fostamatinib disodium hexahydrate), REZLIDHIA (olutasidenib), and GAVRETO (pralsetinib).
TAVALISSE (fostamatinib disodium hexahydrate) is our first product approved by the FDA.
TAVALISSE is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →